| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/28/2005 | US6911543 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| 06/28/2005 | US6911479 Side effect reduction; purity; removal of stereoisomers |
| 06/28/2005 | US6911476 Useful for potentiating glutamate receptor function therefore useful for treating a wide variety of conditions, such as psychiatric and neurological disorders |
| 06/28/2005 | US6911475 For producing a drug for continuous or progressive administration; has a second component comprising L-DOPA |
| 06/28/2005 | US6911466 Amyloid precurser protein lowering agents used in preventing, delaying, or reversing the progression of Alzheimer's disease; identifying agents that increase or decrease the risk of developing Alzheimer's disease |
| 06/28/2005 | US6911461 For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse |
| 06/28/2005 | US6911458 Compounds |
| 06/28/2005 | US6911456 Related to organ systems which respond to estrogen agonists or antagonists; in particular, 2-phenyl-3-aroylbenzothiophenes and 1-(alkylaminoethoxy phenyl)-1-phenyl-2-phenylbut-1-enes have wide application as estrogen agonists |
| 06/28/2005 | US6911452 Central nervous system disorders, sleep disorders, eating disorders. sexual disorders, hypotensive agents |
| 06/28/2005 | US6911448 Piperazine and piperidine compounds |
| 06/28/2005 | US6911445 For reatment of depression, childhood depression, dysthymia, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive-compulsive disorder, cocaine and alcohol addiction |
| 06/28/2005 | US6911443 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 06/28/2005 | US6911440 For the treatment of inflammatory rheumatic/rheumatoid diseases and/or pain, rheumatoid arthritis |
| 06/28/2005 | US6911439 Alpha 4 beta 1 integrin and CD49d/ CD29 (vla-4); antiinflammatory agents |
| 06/28/2005 | US6911429 For therapy of arthritis, inflammatory dermatosis, inflammatory bowel disease, cancer, kidney fibrosis, inflammatory lung disease, obesity, lupus, cardiovascular disease and diabetes mellitus |
| 06/28/2005 | US6911426 Inhibitor of apoptosis proteins (IAP); survivin |
| 06/28/2005 | US6911222 Polar solvent extract of Polygala, polar solvent being water or a mixture of water and methanol or ethanol |
| 06/28/2005 | US6911199 Targeted adenovirus vectors for delivery of heterologous genes |
| 06/28/2005 | CA2174106C Imidazo[1,5-a]quinolines for treatment of anxiety and sleep disorders |
| 06/28/2005 | CA2168097C Substituted 2-aminotetralins |
| 06/28/2005 | CA2159071C 4-arylisoindole analgesics |
| 06/23/2005 | WO2005055999A1 Anticholinergic agent |
| 06/23/2005 | WO2005055993A2 Pharmaceutical preparation containing gabapentin |
| 06/23/2005 | WO2005040121A3 Amides that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| 06/23/2005 | WO2005035488A3 Thiophene-2-carboxamide derivatives and use thereof as cannabinoid cb-1 receptor antagonists |
| 06/23/2005 | WO2005030333A3 Novel derivatives of 4a,5,9,10,11,12-hexahydrobenzofuro[3a,3,2] [2]- benzazepine, method for the production thereof and use thereof in the production of medicaments |
| 06/23/2005 | WO2005014584A9 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 06/23/2005 | WO2005000406A3 Treatment of amyloid- and epileptogenesis-associated diseases |
| 06/23/2005 | WO2004089369B1 Methods and means for treating protein conformational disorders |
| 06/23/2005 | WO2004055026A8 Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 06/23/2005 | WO2004046094A9 Histone deacetylase inhibitors |
| 06/23/2005 | WO2004041258A8 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 06/23/2005 | WO2002068380A8 Synthetic excitatory amino acids |
| 06/23/2005 | US20050138676 Identification of genes involved in Alzheimer's disease using Drosophila melanogaster |
| 06/23/2005 | US20050137414 New aminopropylphosphinic acids |
| 06/23/2005 | US20050137263 e.g., 2-[(4-Ethyl-2-fluorophenyl)amino]-3,4-difluoro-N-(2-hydroxyethoxy)benzamide, is administered to treat arthritis |
| 06/23/2005 | US20050137249 Cyclization at the 5,6-position of the benzo[e]naphtho[3,2-h]azulene, oxepane or thiepane with a mercaptoacetic acid ester followed by etherification, amination or sulfiding at the 2-position; antiarthritic and antiinflammatory agents, analgesics; biosynthesis inhibitors of interleukin-1; nontoxic |
| 06/23/2005 | US20050137242 Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments |
| 06/23/2005 | US20050137239 Thiazole derivatives |
| 06/23/2005 | US20050137229 Novel compounds |
| 06/23/2005 | US20050137225 Aza-bridged bicyclic amine derivatives for use as novel cholinergic receptor ligands |
| 06/23/2005 | US20050137216 Heterocyclic sodium/proton exchange inhibitors and method |
| 06/23/2005 | US20050137214 Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example |
| 06/23/2005 | US20050137208 Chemical compounds |
| 06/23/2005 | US20050137192 Use of compounds such as 4-bromo-9a-butyl-8-chloro-6-fluoro-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one to treat depression |
| 06/23/2005 | US20050137167 Inhibiting FGF growth factor with heparins; antitumor agents; angiogenesis inhibitor; antidiabetic agent treating diabetic retinopathy; antiinflammatory agent; treating retrolenticular fibroplasia, psoriasis, restenosis after angioplasty and after coronary by-pass; chemical intermediates; drug delivery |
| 06/23/2005 | US20050137158 Methods for targeting RNA molecules |
| 06/23/2005 | US20050137134 administering transforming/nerve growth factors to putamen via catheter connected to inflatable pump; increasing dopaminergic neurons; drug delivery kits |
| 06/23/2005 | US20050137128 Modulators of ß-amyloid peptide aggregation |
| 06/23/2005 | US20050136537 Modulating sirtuin deacetylase protein; apoptosis; using flavone, stilbene, isoflavone, sphingosine; stroke; cardiovascular disorders; antiarthritic agents; Alzheimer's disease |
| 06/23/2005 | US20050136113 Dosage form comprising a semipermeable wall defining a cavity having an exit orifice; expandable layer; flow control agent; sustained release push delivery devices having high drug loading with minimized residue |
| 06/23/2005 | US20050136047 Hapten-carrier conjugates for treating and preventing nicotine addiction |
| 06/23/2005 | DE10353657A1 New quinolonyl- or benzopyranonyl-substituted indole derivatives are 5HT(1A)- and/or 5HT(1D)-agonists useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents |
| 06/23/2005 | DE10352450A1 Composition, useful for prophylaxis and/or treatment of Alzheimer's disease, comprises sphingosine, sphingosine biosynthesis activator or sphingosine biodegradation inhibitor |
| 06/23/2005 | CA2550130A1 Agents for preventing and/or treating higher brain dysfunctions |
| 06/23/2005 | CA2549574A1 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist |
| 06/23/2005 | CA2548276A1 Keto lactam compounds and use thereof |
| 06/23/2005 | CA2548033A1 Methods and composition for transplantation of dopaminergic neurons for parkinson's disease |
| 06/23/2005 | CA2548009A1 Naphthyridine derivatives and their use as modulators of muscarinic receptors |
| 06/23/2005 | CA2547863A1 Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy |
| 06/23/2005 | CA2547579A1 Secosterols derived from corals useful as neuroactive substances |
| 06/23/2005 | CA2547391A1 Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament |
| 06/23/2005 | CA2546496A1 Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality |
| 06/23/2005 | CA2490218A1 Extracorporeal photopheresis in combination with anti-tnf treatment |
| 06/22/2005 | EP1544295A1 Salt-inducible kinases 2 and use thereof |
| 06/22/2005 | EP1544281A1 Fat composition |
| 06/22/2005 | EP1544200A1 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE |
| 06/22/2005 | EP1544198A1 A process for the preparation of crystalline losartan potassium |
| 06/22/2005 | EP1544194A1 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| 06/22/2005 | EP1543834A1 Production of hop extracts having oestrogenic and antiproliferative bioactivity |
| 06/22/2005 | EP1543824A2 Thiazole derivatives to counter advanced glycation |
| 06/22/2005 | EP1543722A1 Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy |
| 06/22/2005 | EP1543325A2 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 06/22/2005 | EP1543024A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/22/2005 | EP1543003A2 Imidazo[1,2-a]pyridines |
| 06/22/2005 | EP1543000A1 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| 06/22/2005 | EP1542999A1 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity |
| 06/22/2005 | EP1542991A1 Pyrimidine compounds as therapeutic agents |
| 06/22/2005 | EP1542984A2 Methods of purifying cannabinoids from plant material |
| 06/22/2005 | EP1542981A1 Process for the preparation of 2-amino-4,5,6,7-tetrahydro-6-aminobenzothiaoles from cyclohexanes and cyclohexanones as intermediates |
| 06/22/2005 | EP1542980A1 5-aryltetrazole compounds, compositions thereof, and uses therefor |
| 06/22/2005 | EP1542978A1 Novel bio-active molecules |
| 06/22/2005 | EP1542977A1 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12. |
| 06/22/2005 | EP1542976A1 Substituted 4-(indazol-3-yl)phenols as estrogen receptor (er) ligands and their use in the treatment of inflammatory diseases |
| 06/22/2005 | EP1542972A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 06/22/2005 | EP1542971A1 4-pyrrolidino-phenyl-benzyl ether derivatives |
| 06/22/2005 | EP1542970A1 Pyrrolidone derivatives as maob inhibitors |
| 06/22/2005 | EP1542969A1 Pyrrolidone derivatives as maob inhibitors |
| 06/22/2005 | EP1542964A2 Compounds for the treatment of alzheimer's disease |
| 06/22/2005 | EP1542961A1 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
| 06/22/2005 | EP1542948A2 Novel biphenyl and biphenyl-like cannabinoids |
| 06/22/2005 | EP1542724A2 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 06/22/2005 | EP1542719A2 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 06/22/2005 | EP1542698A2 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s) |
| 06/22/2005 | EP1542697A1 Modified release formulations of oxcarbazepine and derivatives thereof |
| 06/22/2005 | EP1542692A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| 06/22/2005 | EP1542686A2 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 06/22/2005 | EP1542678A1 1H-1,2,4-TRIAZOLE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID-CB sb 1 /sb RECEPTOR LIGANDS |
| 06/22/2005 | EP1542676A1 Methods of treating benzodiazepine site (bzd-s) associated syndromes using 2' hydroxyflavonoids |
| 06/22/2005 | EP1542670A1 Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities |